Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Tuesday 23 December 2025

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Digital

pharmaphorum podcast Episode 236, Tarek Samad, Lundbeck

An AI supercomputer and discovering next-gen brain disorder ...

Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.

Sales & Marketing

Patent spelled out in wooden blocks on top of legal documents

The hidden IP problem holding innovators back

For organisations active in the US market, the impact of patent marking is financial, not administrative.

Patients

Patient struggling to take their medication

The humans the algorithms can't reach

Patients don’t start, stay on, or return to therapy because they receive a notification at the right time.

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

Sales & Marketing

Doctors and medical affairs round a table in discussion

Breaking tradition to reimagine medical affairs workflows fo...

To stay relevant, medical affairs teams must adapt how they work to meet new demands with greater agility and efficiency.

Digital

pharmaphorum podcast Episode 208a, Dr Jay Anders

Improving ROI on AI investments and data quality, with Dr Ja...

Dr Jay Anders, chief medical officer for Medicomp Systems, discusses why he believes that the only way to solve AI ROI issues is to solve data quality

Oncology

Chemicals in test tubes on a rack in a lab

Advancing radiopharmaceutical development: Preclinical preci...

Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.

R&D

Glasgow

From pilots to patients: Why the UK must rethink NHS innovat...

At PharmaTech Integrates in Glasgow, speakers from government, academia, the NHS, and pharma sought to define the sector’s path forward.

Load more results

Sales & Marketing

Sales & Marketing

Patent spelled out in wooden blocks on top of legal documents

The hidden IP problem holding innovators back

For organisations active in the US market, the impact of patent marking is financial, not administrative.

Sales & Marketing

Doctors and medical affairs round a table in discussion

Breaking tradition to reimagine medical affairs workflows fo...

To stay relevant, medical affairs teams must adapt how they work to meet new demands with greater agility and efficiency.

Digital

Digital

pharmaphorum podcast Episode 236, Tarek Samad, Lundbeck

An AI supercomputer and discovering next-gen brain disorder ...

Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.

Digital

pharmaphorum podcast Episode 233, Patrick Leung, Faro Health

AI for the planet, AI for life sciences – with Patrick Leung

Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials.

Market Access

Market Access

Group of ethnically diverse women

Women's health: Predictions for 2026

A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.

Market Access

Images of pills on dominoes pieces, one being removed from the line

UK pharma policy at a turning point: NICE threshold reform, ...

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

Editor's Picks

AC Immune says Parkinson's drug slows progression

UK confirms lower clawback rate for NHS medicines

Antibiotic is first approval in FDA national priority scheme

Agreement reached on EU's new pharma legislation

UK teams up with Singapore on healthtech regulation

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Cancer cell on pink background

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Oncology

Medically accurate representation of a cancer cell

Radiopharmaceutical innovation: Giving cancer drugs second c...

Molecular recycling could transform the economics and innovation of oncology drug discovery.

Patients

Patients

Patient struggling to take their medication

The humans the algorithms can't reach

Patients don’t start, stay on, or return to therapy because they receive a notification at the right time.

Patients

pharmaphorum podcast Episode 234, Amy Bucher, Lirio

Delivering the right behavioural ingredients for the moment,...

Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.

Patients

pharmaphorum podcast Episode 228, Ruth Chambers, Raparu Consult CIC

The NHS, system burden, and a transformation prescription, w...

Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, discusses her book on the NHS.

R&D

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

R&D

A white rat in amongst lab bottles

Beyond good intentions: How life sciences can prove its read...

While support for reducing animal use has never been stronger, the path to broad adoption is steep and complex.

R&D

Female technician in the lab

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

Editor's Picks

AC Immune says Parkinson's drug slows progression

UK confirms lower clawback rate for NHS medicines

Antibiotic is first approval in FDA national priority scheme

Agreement reached on EU's new pharma legislation

UK teams up with Singapore on healthtech regulation

Digital

pharmaphorum podcast Episode 236, Tarek Samad, Lundbeck

An AI supercomputer and discovering next-gen brain disorder ...

Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company